APA (7th ed.) Citation

Maeda, O., Tanaka, C., Furukawa, K., Miyata, K., Shimizu, D., Sugita, S., . . . Ando, Y. (2026). Feasibility Study of Trifluridine/Tipiracil and Zolbetuximab as Third‐ or Later‐Line Chemotherapy for CLDN18.2‐Positive and HER2‐Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Study Protocol. Cancer Medicine, 15(5), 1. https://doi.org/10.1002/cam4.71981

Chicago Style (17th ed.) Citation

Maeda, Osamu, et al. "Feasibility Study of Trifluridine/Tipiracil and Zolbetuximab as Third‐ or Later‐Line Chemotherapy for CLDN18.2‐Positive and HER2‐Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Study Protocol." Cancer Medicine 15, no. 5 (2026): 1. https://doi.org/10.1002/cam4.71981.

MLA (9th ed.) Citation

Maeda, Osamu, et al. "Feasibility Study of Trifluridine/Tipiracil and Zolbetuximab as Third‐ or Later‐Line Chemotherapy for CLDN18.2‐Positive and HER2‐Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Study Protocol." Cancer Medicine, vol. 15, no. 5, 2026, p. 1, https://doi.org/10.1002/cam4.71981.